AWARD-PEDS trial results

Inclusion Criteria: * Have type 2 diabetes, treated with diet and exercise, with or without metformin and/or basal insulin. Metformin and/or basal insulin dose must be stable for at least 8 weeks prior to study screening. * Have HbA1c \>6.5% to ≤11% at screening visit. If newly diagnosed and not on medicine for diabetes, HbA1c must be between \>6.5 % to ≤9%. * Have a BMI (body mass index) \>85 percentile for age, gender and body weight ≥50 kilograms (110 pounds). Exclusion Criteria: * Known type 1 diabetes, or positive GAD65 or IA2 antibodies, or history of diabetic ketoacidosis or hyperglycemic hyperosmolar syndrome. * A history of, or at risk for pancreatitis. * Self or family history of Multiple Endocrine Neoplasia (MEN) type 2A or B, thyroid C-cell hyperplasia or medullary thyroid cancer, or a blood calcitonin result ≥20 picograms per milliliter (pg/ml) at screening. * A systolic blood pressure of ≥160 millimeters of mercury (mmHg) or diastolic ≥100 mmHg. * Active or treated cancer. * A blood disorder where an accurate HbA1c may not be obtainable. * A female of childbearing age, sexually active and not on birth control. * Pregnant or plan to be pregnant during the study, or breastfeeding. * Taking any diabetic medication other than metformin or basal insulin and have not stopped it 3 months prior to the screening visit (6 weeks for bolus or mealtime insulin). * Have taken oral steroids within the last 60 days or more than 20 days use within the past year or 1000 micrograms fluticasone propionate per day. * Using prescription weight loss medications in the last 30 days, or plan to use. * Taking psychiatric medications for depression or illness or attention deficit hyperactivity disorder (ADHD) if, the doses has changed within the last 3 months.